{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:34:40Z","timestamp":1761129280921,"version":"3.40.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.antiviral.2015.12.005","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T09:59:25Z","timestamp":1450519165000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing"],"prefix":"10.1016","volume":"126","author":[{"given":"Assar","family":"Bergfors","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-0317","authenticated-orcid":false,"given":"Dani\u00ebl","family":"Leenheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Bergqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Ameur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Lennerstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.12.005_bib1","unstructured":"Burrows-Wheeler Aligner [WWW Document], n.d. URL http:\/\/bio-bwa.sourceforge.net\/(accessed 21.5.14.)."},{"key":"10.1016\/j.antiviral.2015.12.005_bib2","unstructured":"LCI-richtlijn Hepatitis C [WWW Document], n.d. URL http:\/\/www.rivm.nl\/Documenten_en_publicaties\/Professioneel_Praktisch\/Richtlijnen\/Infectieziekten\/LCI_richtlijnen\/LCI_richtlijn_Hepatitis_C (accessed 27.2.14.)."},{"key":"10.1016\/j.antiviral.2015.12.005_bib3","unstructured":"SAMtools [WWW Document], n.d. URL http:\/\/samtools.sourceforge.net\/(accessed 21.5.14.)."},{"key":"10.1016\/j.antiviral.2015.12.005_bib4","unstructured":"WHO | Hepatitis C [WWW Document], n.d. WHO. URL http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/(accessed 27.1.14.)."},{"key":"10.1016\/j.antiviral.2015.12.005_bib5","unstructured":"Accuscript RT Products, n.d. AccuScript High Fidelity Reverse Transcriptase Products. Available at: http:\/\/www.chem.agilent.com\/library\/datasheets\/public\/tb108_71067.pdf."},{"key":"10.1016\/j.antiviral.2015.12.005_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2013.206","article-title":"Novel Therapeutic Approaches for hepatitis C","volume":"95","author":"Au","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2015.12.005_bib7","unstructured":"Babraham Bioinformatics \u2013 FastQC A Quality Control tool for High Throughput Sequence Data [WWW Document], n.d. URL http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/(accessed 5.21.14.)."},{"year":"2012","series-title":"Evaluating the Potential of New Sequencing Technologies for Genotyping and Variation Discovery in Human Data","author":"Carneiro","key":"10.1016\/j.antiviral.2015.12.005_bib8"},{"key":"10.1016\/j.antiviral.2015.12.005_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1471-2164-13-375","article-title":"Pacific biosciences sequencing technology for genotyping and variation discovery in human data","volume":"13","author":"Carneiro","year":"2012","journal-title":"BMC Genom."},{"key":"10.1016\/j.antiviral.2015.12.005_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12885-015-1046-y","article-title":"Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing","volume":"15","author":"Cavelier","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.antiviral.2015.12.005_bib11","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1093\/nar\/24.18.3546","article-title":"PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases","volume":"24","author":"Cline","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.12.005_bib12","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a Pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2015.12.005_bib13","doi-asserted-by":"crossref","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients","volume":"10","author":"Dietz","year":"2015","journal-title":"PloS One"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.antiviral.2015.12.005_bib14","first-page":"A38","article-title":"The prevalence of HCV NS5A, nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir sofosbuvir\u00a0\u00b1\u00a0RBV in the Phase 3 ION studies","volume":"19","author":"Dvory-Sobol","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.12.005_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02490-13","article-title":"Dynamic imaging of the hepatitis C virus NS5A protein during a productive infection","author":"Eyre","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib16","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r\u2013Ombitasvir and Dasabuvir with or without Ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.12.005_bib17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1574-6976.2012.00338.x","article-title":"DNA replication fidelity in Escherichia coli: a multi-DNA polymerase affair","volume":"36","author":"Fijalkowska","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2015.12.005_bib18","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in\u00a0vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.005_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in\u00a0vitro and in\u00a0vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatol. Balt. Md"},{"key":"10.1016\/j.antiviral.2015.12.005_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.12.005_bib21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s007050170078","article-title":"Intracellular hepatitis C virus RNA-dependent RNA polymerase activity","volume":"146","author":"Goobar-Larsson","year":"2001","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J.\u00a0Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jhep.2009.08.004","article-title":"The long and winding road leading to the identification of the hepatitis C virus","volume":"51","author":"Houghton","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib24","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2014.0031","article-title":"Primer ID Informs next-generation sequencing Platforms and Reveals pre-existing drug resistance mutations in the HIV-1 reverse transcriptase coding domain","author":"Keys","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2015.12.005_bib25","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(14)61390-8","article-title":"Lack of impact of baseline resistance-associated variants (RAVs) on treatment outcome in the aviator study with ABT-450\/r, ABT-333 and ABT-267,\u00a0+\/\u2212 ribavirin","author":"Krishnan","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.005_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A\u00a0phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24 weeks","author":"Lawitz","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib30","article-title":"Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden","volume":"1\u20138","author":"Lindstr\u00f6m","year":"2015","journal-title":"Infect. Dis. Lond. Engl."},{"key":"10.1016\/j.antiviral.2015.12.005_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","author":"Lontok","year":"2015","journal-title":"Hepatol. Balt. Md"},{"key":"10.1016\/j.antiviral.2015.12.005_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-1119(91)90480-Y","article-title":"High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus","volume":"108","author":"Lundberg","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.antiviral.2015.12.005_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1478-3231.2011.02684.x","article-title":"An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region","volume":"32","author":"Nakano","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.12.005_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","author":"Nelson","year":"2015","journal-title":"Hepatol. Balt. Md"},{"key":"10.1016\/j.antiviral.2015.12.005_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.005_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients","volume":"10","author":"Paolucci","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2015.12.005_bib37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.compbiolchem.2005.11.002","article-title":"A\u00a0quantitative model of error accumulation during PCR amplification","volume":"30","author":"Pienaar","year":"2006","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.12.005_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.005_bib39","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2015.12.005_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvir \u00b1 RBV","author":"Sarrazin","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.005_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or Untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.12.005_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsd\u00f3ttir","year":"2013","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.antiviral.2015.12.005_bib43","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/AAC.05977-11","article-title":"Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.005_bib44","series-title":"Abstract 1881 presented at the 63rd annual meeting of the AASLD, Boston, United States","article-title":"Antiviral activity and resistance profiles for ABT-267, a novel HCV NS5A inhibitor, in\u00a0vitro and during 3-day monotherapy in HCV genotype-1 (GT1)-infected treatment-na\u00efve subjects","author":"Williams","year":"2012"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T15:31:21Z","timestamp":1537111881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215300449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":44,"alternative-id":["S0166354215300449"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}